THOMAS SMURA: Open Payments
NPI 1417583998 · MELBOURNE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,021 in 54 payments from 13 companies in 2025. Trend: 2023 $615 · 2024 $1,419 · 2025 $1,021
Food & beverage: $1,021
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $182 |
| Teva Pharmaceuticals USA, Inc. | 5 | $100 |
| E.R. Squibb & Sons, L.L.C. | 4 | $89 |
| Alkermes, Inc. | 4 | $83 |
| Axsome Therapeutics, Inc. | 3 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Neurocrine BioSciences, Inc. | 3 | $58 |
| Lundbeck LLC | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
Products named: VRAYLAR, CAPLYTA, UZEDY, COBENFY, ARISTADA, Auvelity, TRINTELLIX, INGREZZA.
Industry payments across FL — which companies pay providers there.
